Observational studyThe journal of headache and pain2017
Copeptin for risk stratification in non-traumatic headache in the emergency setting: a prospective multicenter observational cohort study.
Observational study in The journal of headache and pain, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01174901 (Copeptin for Risk Stratification in Non-traumatic Headache in the Emergency Setting - The CoHead Study), which is not on this map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Copeptin for Risk Stratification in Non-traumatic Headache in the Emergency Setting - The CoHead Study
Who cites it
9 citing papers in PubMed, 13 citations in OpenAlex.
- Earmuff and eye mask in the treatment of acute primary headache in emergency department: a randomized controlled open label study.BMC emergency medicine · 2025Trial
- Diagnostic Value of Neurofilament Light Chain and Glial Fibrillary Acidic Protein in Differentiating Primary From Serious Secondary Headache.European journal of neurology · 2026Article
- Analysis of brain scan findings requested from individuals visiting the emergency department outpatient clinic with headache.Northern clinics of Istanbul · 2025Article
- Early detection of stroke at the sudden sensorineural hearing loss stage.Frontiers in neurology · 2023Article
- Relevance of cortisol and copeptin blood concentration changes in an experimental pain model.Scientific reports · 2022Article
- Biomarkers Utility: At the Borderline between Cardiology and Neurology.Journal of cardiovascular development and disease · 2021Review
- Activation of Vasopressin System During COVID-19 is Associated With Adverse Clinical Outcomes: An Observational Study.Journal of the Endocrine Society · 2021Article
- Nontraumatic Headache in Adult Emergency Patients: Prevalence, Etiologies, and Radiological Findings.Journal of clinical medicine · 2020Article
- Novel Biomarkers to Detect Target Organ Damage in Acute Hypertension.Current hypertension reports · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn the emergency setting, non-traumatic headache is a benign symptom in 80% of cases, but serious underlying conditions need to be ruled out. Copeptin improves risk stratification in several acute diseases. Herein, we investigated the value of copeptin to discriminate between serious secondary headache and benign headache forms in the emergency setting.
methodsPatients presenting with acute non-traumatic headache were prospectively enrolled into an observational cohort study. Copeptin was measured upon presentation to the emergency department. Primary endpoint was serious secondary headache defined by a neurologic cause requiring immediate treatment of the underlying disease. Secondary endpoint was the combination of mortality and hospitalization within 3 months. Two board-certified neurologist blinded to copeptin levels verified the endpoints after a structured 3-month-telephone interview.
resultsOf the 391 patients included, 75 (19%) had a serious secondary headache. Copeptin was associated with serious secondary headache (OR 2.03, 95%CI 1.52-2.70, p < 0.0001). Area under the curve (AUC) for copeptin to identify the primary endpoint was 0.70 (0.63-0.76). After adjusting for age > 50, focal-neurological abnormalities, and thunderclap onset of symptoms, copeptin remained an independent predictive factor for serious secondary headache (OR 1.74, 95%CI 1.26-2.39, p = 0.001). Moreover, copeptin improved the AUC of the multivariate logistic clinical model (p-LR-test < 0.001). Even though copeptin values were higher in patients reaching the secondary endpoint, this association was not significant in multivariate logistic regression.
conclusionsCopeptin was independently associated with serious secondary headache as compared to benign headaches forms. Copeptin may be a promising novel blood biomarker that should be further validated to rule out serious secondary headache in the emergency department.
trial registrationStudy Registration on 08/02/2010 as NCT01174901 at clinicaltrials.gov.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.